The company will present a non-inferiority analysis suggesting Norvasc (amlodipine) is similar to the diuretic chlorthalidone in preventing hypertension outcomes during a June 15 meeting of FDA's Cardiovascular & Renal Drugs Advisory Committee, the agency says.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.
The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.
